Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs: Annals of Hematology

D. Pastore, B. Bruno, P. Carluccio, M.S. De Candia, S. Mammoliti, C. Borghero, A. Chierichini, F. Pavan, M. Casini, M. Pini, L. Nassi, R. Greco, F.P. Tambaro, P. Stefanoni, G. Console, F. Marchesi, L. Facchini, A. Mussetti, M. Cimminiello, F. SaglioD. Vincenti, S. Falcioni, P. Chiusolo, J. Olivieri, A. Natale, M. Faraci, S. Cesaro, S. Marotta, A. Proia, I. Donnini, D. Caravelli, E. Zuffa, A.P. Iori, E. Soncini, V. Bozzoli, G. Pisapia, R. Scalone, O. Villani, A. Prete, A. Ferrari, M. Menconi, G. Mancini, F. Gigli, G. Gargiulo, F. Patriarca, F. Bonifazi

Research output: Contribution to journalArticlepeer-review


A survey within hematopoietic stem cell transplant (HSCT) centers of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) was performed in order to describe current antiemetic prophylaxis in patients undergoing HSCT. The multicenter survey was performed by a questionnaire, covering the main areas on chemotherapy-induced nausea and vomiting (CINV): antiemetic prophylaxis guidelines used, antiemetic prophylaxis in different conditioning regimens, and methods of CINV evaluation. The survey was carried out in November 2016, and it was repeated 6 months after the publication of the Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO) specific guidelines on antiemetic prophylaxis in HSCT. The results show a remarkable heterogeneity of prophylaxis among the various centers and a significant difference between the guidelines and the clinical practice. In the main conditioning regimens, the combination of a serotonin3 receptor antagonist (5-HT3-RA) with dexamethasone and neurokin1 receptor antagonist (NK1-RA), as recommended by MASCC/ESMO guidelines, increased from 0 to 15% (before the publication of the guidelines) to 9–30% (after the publication of the guidelines). This study shows a lack of compliance with specific antiemetic guidelines, resulting mainly in under-prophylaxis. Concerted strategies are required to improve the current CINV prophylaxis, to draft shared common guidelines, and to increase the knowledge and the adherence to the current recommendations for CINV prophylaxis in the specific field of HSCT. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
Original languageEnglish
Pages (from-to)867-875
Number of pages9
JournalAnn. Hematol.
Issue number4
Publication statusPublished - 2020


  • Antiemetic prophylaxis
  • CINV
  • Hematopoietic stem cell transplantation
  • MASCC/ESMO guidelines
  • antiemetic agent
  • aprepitant
  • bendamustine
  • busulfan
  • carmustine
  • cyclophosphamide
  • cytarabine
  • dexamethasone
  • etoposide
  • fludarabine
  • fotemustine
  • melphalan
  • palonosetron
  • thiotepa
  • antineoplastic agent
  • myeloablative agent
  • adult
  • antiemetic prophylaxis
  • Article
  • cancer chemotherapy
  • chemotherapy induced nausea and vomiting
  • controlled study
  • hematopoietic stem cell transplantation
  • human
  • Italy
  • malignant neoplasm
  • practice guideline
  • priority journal
  • prophylaxis
  • publication
  • questionnaire
  • transplantation conditioning
  • adverse event
  • allograft
  • autotransplantation
  • clinical practice
  • clinical trial
  • health care survey
  • multicenter study
  • nausea
  • protocol compliance
  • vomiting
  • Allografts
  • Antiemetics
  • Antineoplastic Combined Chemotherapy Protocols
  • Guideline Adherence
  • Health Care Surveys
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Myeloablative Agonists
  • Nausea
  • Practice Guidelines as Topic
  • Practice Patterns, Physicians'
  • Transplantation Conditioning
  • Transplantation, Autologous
  • Vomiting


Dive into the research topics of 'Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs: Annals of Hematology'. Together they form a unique fingerprint.

Cite this